Evidence map›Paper›PMID 41634421›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026

Delayed recovery following myasthenic exacerbation and subsequent endplate-protecting treatment.

Anna Mück, Sonja Genau, Julia Emde, Christoph Best, Steffen Pfeuffer, Heidrun H Krämer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anna MückDepartment of Neurology, Justus Liebig University, Klinikstrasse 33, D-35392, Giessen, Germany.ORCID http://orcid.org/0009-0005-6943-5867
Sonja GenauDepartment of Neurology, Justus Liebig University, Klinikstrasse 33, D-35392, Giessen, Germany.
Julia EmdeDepartment of Neurology, Justus Liebig University, Klinikstrasse 33, D-35392, Giessen, Germany.
Christoph BestDepartment of Neurology, Philipps-University, Marburg, Germany.
Steffen Pfeuffer *Department of Neurology, Justus Liebig University, Klinikstrasse 33, D-35392, Giessen, Germany.
Heidrun H Krämer *Department of Neurology, Justus Liebig University, Klinikstrasse 33, D-35392, Giessen, Germany. Heidrun.Kraemer@neuro.med.uni-giessen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endplate-protecting therapies have improved treatment of myasthenia gravis and indicate a rapid onset of their treatment effect. Currently, these substances can be used following myasthenic exacerbation (ME). Clinical worsening due to ME however often results in prolonged recovery. We here evaluated the treatment courses of patients having received endplate-protecting treatment following ME. Among 12 patients with ME described here, seven received endplate-protecting therapies. Our findings indicate that acceptable recovery usually takes nine months. In the lights of recent trials for treatment of myasthenia, our findings implicate that the effectiveness of novel substances should be judged only after sufficient observation periods.

Indexed as

Myasthenia GravisRecovery of FunctionAdultAgedCholinesterase InhibitorsDisease ProgressionFemaleHumansMaleMiddle AgedPyridostigmine BromideTreatment OutcomeCholinesterase InhibitorsPyridostigmine BromideEndplate-protecting treatmentMyasthenia gravisMyasthenic exacerbationReal-world evidence

Identifiers

PMID41634421
PMCPMC12868007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.